Answers are grounded in this paper and cite their sources.
Introduction:The SARS-CoV-2 epidemic has infected and killed millions of people worldwide since 2019.Therapies available for SARS-CoV-2 disease are limited due to the sudden emergence of the virus.The need for appropriate vaccines to combat this dangerous virus is essential.Induction of specific antibodies against SARS-CoV-2 virus is mainly by nucleocapsid (N), membrane (M) and spike glycoprotein (S) proteins.On the other hand, cost-effective and fast methods for the expression and purification of recombinant proteins that retain antigenic properties are essential for vaccine development.Methods: A DNA fragment encoding the N, M and S1 proteins was inserted into pET28a vector to make an expression plasmid.The recombinant protein was then expressed in Escherichia coli Rosetta strain and purified by Ni-NTA column, followed by confirmation by SDS-PAGE and Western blotting.Results: PCR results showed that the gene was inserted correctly into the expression vector.The expression of the recombinant protein containing N, M and S1 proteins from SARS CoV-2 was optimized in a bacterial system.The recombinant protein was successfully purified from Ni-NTA column with a high yield Conclusion: Upon further evaluations, this cost-effective approach for the production of recombinant antigenic proteins in E. coli (Rosetta), could potentially be used for the development of vaccines against coronaviruses infections.
No takes yet. Share an insight, caveat, or question.
Shirazi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: